MK-6096 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Neuropathy, Painful
Conditions
Diabetic Neuropathy, Painful
Trial Timeline
Mar 26, 2012 → Apr 18, 2013
NCT ID
NCT01564459About MK-6096 + Placebo
MK-6096 + Placebo is a phase 2 stage product being developed by Merck for Diabetic Neuropathy, Painful. The current trial status is completed. This product is registered under clinical trial identifier NCT01564459. Target conditions include Diabetic Neuropathy, Painful.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01564459 | Phase 2 | Completed |
| NCT01513291 | Phase 2 | Completed |
Competing Products
20 competing products in Diabetic Neuropathy, Painful